Omega Therapeutics Stock Today
| OMGA Stock | USD 0.80 0.06 6.98% |
Performance0 of 100
| Odds Of DistressOver 85
|
Omega Therapeutics is trading at 0.8 as of the 28th of November 2024, a 6.98 percent decrease since the beginning of the trading day. The stock's open price was 0.86. Omega Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Omega Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 55.37 M outstanding shares of which 6.36 M shares are now shorted by private and institutional investors with about 16.34 trading days to cover. More on Omega Therapeutics
Moving together with Omega Stock
| 0.66 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.69 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | INKT | Mink Therapeutics | PairCorr |
Moving against Omega Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Omega Stock Highlights
| CEO President | Mahesh Karande | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOmega Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Omega Therapeutics' financial leverage. It provides some insight into what part of Omega Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Omega Therapeutics (OMGA) is traded on NASDAQ Exchange in USA. It is located in 20 Acorn Park Drive, Cambridge, MA, United States, 02140 and employs 93 people. Omega Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.09 M. Omega Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 55.37 M outstanding shares of which 6.36 M shares are now shorted by private and institutional investors with about 16.34 trading days to cover.
Omega Therapeutics currently holds about 173.66 M in cash with (91.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Omega Therapeutics Probability Of Bankruptcy
Ownership AllocationOmega Therapeutics owns a total of 55.37 Million outstanding shares. The majority of Omega Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Omega Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Omega Therapeutics. Please pay attention to any change in the institutional holdings of Omega Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Omega Ownership Details
Omega Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| 72 Investment Holdings, Llc | 2024-09-30 | 352.9 K | |
| Junked Platinum Investment Management Ltd | 2024-09-30 | 346.4 K | |
| State Treasurer State Of Michigan | 2024-09-30 | 314.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 230.8 K | |
| Squarepoint Ops Llc | 2024-06-30 | 222.4 K | |
| Jane Street Group Llc | 2024-06-30 | 213.5 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 190.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 188 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 119 K | |
| Flagship Ventures Management, Inc. | 2024-06-30 | 29.2 M | |
| Fmr Inc | 2024-09-30 | 6.1 M |
Omega Therapeutics Historical Income Statement
Omega Stock Against Markets
Omega Therapeutics Corporate Management
| JD Esq | Chief Secretary | Profile | |
| Kevin McManus | Chief Officer | Profile | |
| Kaan Certel | Chief Officer | Profile | |
| Barbara Chan | Principal Office | Profile | |
| Noubar Afeyan | CoFounder Chairman | Profile | |
| Jennifer Nelson | Senior Research | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.